Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
At around $1,500, Eli Lilly (LLY) looks fully valued or slightly overvalued based on the speaker’s analysis; their scenario-based value was about $1,200, so avoid chasing shares at the cited price.
LLY still has strong growth and the speaker expects Q4 to beat estimates, but future returns depend on sustained GLP-1 sales; monitor revenue growth, demand saturation, and patent risks before reconsidering.
No actionable trade is supported for the AI-chip names discussed: the comments on Maddox and SambaNova lacked a clear thesis, valuation, or timeframe.
Detailed Analysis
Eli Lilly (LLY)
Lilly was described as trading near $1,500. The speaker said GLP-related sales were about $17.1 billion in the last quarter, up from $16.2 billion the quarter before, while questioning whether growth is slowing. The speaker expected Q4 to beat their estimate.
Lilly’s revenue grew 36% in the last quarter, and the speaker cited roughly $41 billion of net debt, or about a year of earnings.
The discussion referenced projected revenue of $65 billion and $80 billion in 2027. The speaker considered the $65 billion figure nearly certain, but said outcomes of $85 billion or $90 billion would make a significant difference to the growth outlook.
The speaker said Lilly looked fairly valued, or perhaps slightly overvalued, if GLP-1 sales persist indefinitely. Using an 8% discount rate, their valuation exercise produced a share value of about $1,200.
The speaker said Lilly would only look undervalued under a much more optimistic GLP-1 scenario, but had difficulty believing the drugs could generate $150 billion in revenue. They modeled a scenario in which a drug referred to as “Red or True Tide” became the best-selling drug of all time, generating $62 billion, alongside $80 billion for Mounjaro.
The speaker said they were not long Lilly.
Takeaways
The discussion presents Lilly as a strong-growth business, but its valuation depends heavily on how much GLP-1 revenue the market expects and how long that revenue lasts.
The speaker’s $1,200 valuation is a scenario-based estimate, not a firm price target or recommendation. At the roughly $1,500 price cited, their comments indicate a cautious view.
Lilly’s quarterly growth and Q4 outlook are positive points in the discussion; uncertainty about future GLP-1 growth is the central counterweight.
GLP-1 Drugs and Products
The conversation focused on the long-term growth prospects of Lilly’s GLP-1 business, including Mounjaro and products referred to in the transcript as Foundayo and “Red or True Tide.” The latter name is unclear in the transcript.
The speaker raised questions about how Lilly will manage its GLP-1 portfolio, particularly around intellectual-property rights.
The discussion questioned whether GLP-1 demand could eventually saturate and noted that products could face generic competition after patent protection expires.
The speaker said a small-molecule product could eventually become generic, but also suggested that Lilly might have substantial cash by the time patents expire.
Takeaways
The main investment issue is whether GLP-1 sales can keep growing at the pace implied by optimistic forecasts, rather than whether the category is currently large.
Patent duration, generic competition, and the trajectory of demand are key uncertainties raised in the discussion. The transcript does not provide specific timelines for patent expirations or generic entry.
AI Compute and Semiconductor Startups
The speaker mentioned SambaNova, Maddox, Etched, D-Matrix, Neurophos, and Positron, described as a Lambda spinout.
The speaker said they were less bullish on SambaNova and found Maddox interesting. No specific valuation, financial details, or investment recommendation was given for these companies.
Grok and NVIDIA (NVDA) were also mentioned, but the discussion did not provide a clear investment thesis for either.
Takeaways
The names point to interest in AI computing and semiconductor-related companies, but the comments are too brief to support a company-level investment conclusion.
The only explicit directional views were less bullish sentiment on SambaNova and interest in Maddox; neither was accompanied by a specific rationale or recommendation.
Ask about this postAnswers are grounded in this post's content.
Video Description
Sign Up For Godel Terminal: https://app.godelterminal.com/?via=shkreliplanet
Use Promo Code: Shkreliplanet For 30% Off The First Month
Follow Martin Shkreli On Twitter: https://twitter.com/MartinShkreli
Follow Martin Shkreli On Instagram: https://www.instagram.com/martinshkreli15/
Trade on Interactive Brokers: https://tinyurl.com/ye2aj6uz
Book Recommendation About Stocks & Investing:
Common Stocks and Uncommon Profits By Phil Fisher: https://amzn.to/3MCip3R
The Intelligent Investor By Benjamin Graham: https://amzn.to/3Xn7jnY
One Up On Wall Street By Peter Lynch: https://amzn.to/3XlrfYx